Perioperative multiple low-dose Dexamethasones improves postoperative clinical outcomes after Total knee arthroplasty

Yuangang Wu 1†, Xiaoxi Lu 2,3†, Yimei Ma 2,3, Yi Zeng 1, Xianchao Bao 1, Huazhang Xiong 1 and Bin Shen 1*

Abstract

Background: The purpose of this study was to investigate the efficacy and safety of multiple low-dose dexamethasones in primary total knee arthroplasty (TKA).

Methods: One hundred fifty patients were equally randomized into 3 groups: Group A (n = 50) received 2 doses of normal saline only; Group B (n = 50) received with 1 dose of intravenous dexamethasone and 1 dose of normal saline; Group C (n = 50) received with 2 doses of intravenous dexamethasone. The clinical outcomes and complications were assessed.

Results: The CRP and IL-6 were significantly lower in Group C and B than Group A at 24, 48, and 72 h postoperatively (P < 0.001 for all). The intensity of postoperative nausea and vomiting (PONV) in Group C was lower than Group A at 24 (P = 0.005, P = 0.041) and 72 h (P = 0.017, P = 0.031) postoperatively and Group B at 24 h (P = 0.027, P = 0.019) postoperatively. Pain were significantly less in Group C than Group A at 24 h (P = 0.001, P = 0.037) and Group B 24 h (P = 0.030) postoperatively. Patients in Group C had better range of motion (ROM) and satisfaction than Group A (P < 0.001, P = 0.002) and B (P = 0.001, P = 0.043). No differences were found in complications.

Conclusions: The administration of 10 mg dexamethasone 1 h before the surgery, and repeated at 6 h postoperatively can significantly reduce the level of postoperative CRP and IL-6 and the incidence of PONV, relieve pain, achieve an additional analgesic effect, and improve the early ROM compared with the other two groups in TKA.

Level of Evidence: Therapeutic Level I.

Trial registration: The Chinese Clinical Trial Registry (ChiCTR1800017036). Registered on July 9, 2018.

Keywords: Total knee arthroplasty, Dexamethasones, Clinical outcomes, Randomized controlled study

Background

Total knee arthroplasty (TKA) has become a successful surgical method for the treatment of severe knee diseases [1–3]. TKA, however, involves extensive osteotomy, soft tissue release and surgical trauma, which often lead to severe postoperative inflammatory reactions [4–6]. Consequently, patients can experience severe pain in the early postoperative period [7, 8], accompanied by postoperative nausea and vomiting (PONV) [9–11], and a prolonged length of stay (LOS) [12]. Pain and PONV may hinder the early recovery of TKA, resulting in patients dissatisfaction [13–16]. Therefore, it is better to improve the fast-track recovery of patients in reducing postoperative inflammation, relieving pain and preventing PONV.

Glucocorticoids, which have powerful anti-inflammatory and antiemetic effects, are widely used in perioperative management, such as abdominal [17, 18], gynaecologic [19], and TKA surgery [20–22], for reducing the postoperative inflammatory response, alleviating postoperative pain and preventing PONV. However, the most suitable protocol...
as previously reported, glucocorticoids were given at a single and low dose, with fewer samples in most previous studies [23–25]. In addition, concerns regarding the adverse effects of glucocorticoid therapy, including infection and gastrointestinal bleeding, have potentially limited its widespread use in TKA [26]. Last, although the administration of the drug provides better pain and vomiting relief than traditional methods, many patients still suffer from it at the initial stage after surgery [19, 22, 27].

The current study was therefore designed to compare the effectiveness and safety of multiple low doses of dexamethasone in patients following primary TKA by evaluating: (1) whether multiple low doses of dexamethasone reduce postoperative inflammatory markers and the incidence of PONV; (2) whether multiple low doses of dexamethasone relieve pain and provide an additional analgesic effect, improving the range of motion (ROM) and patient satisfaction; and (3) whether multiple low doses of dexamethasone are safe in primary TKA.

Methods
Study design and patients
This randomized controlled trial was approved by the institutional ethics committee and written informed consent was obtained from each patient. The study was registered in the Chinese Clinical Trial Registry on 09/07/2018 (ChiCTR1800017036). All consecutive patients with a diagnosis of end-stage osteoarthritis following primary unilateral TKA were enrolled for inclusion in the study. The exclusion criteria were as follows: rheumatoid arthritis, revision surgery, allergy to the dexamethasone and tranexamic acid, administration of the glucocorticoid 3 months before surgery, alcohol dependence, and severe liver and kidney deficiency and body mass index (BMI) > 35 kg/m². Patients were randomly assigned to three groups containing 50 patients with a list generated by a computer, and randomization was blind and performed with the use of sealed envelopes at a ratio of 1:1:1 to be opened just prior to surgery.

Patients in the Group A was given intravenously 2 mL of normal saline solution 1 h before the surgery and repeated 6 h after surgery. Patients in the Group B was given intravenously 10 mg dexamethasone (2 mL, Tianjin Kingyork group Co., Ltd., China) 1 h before the surgery and repeated intravenously 2 mL of normal saline solution 6 h after surgery. Patients in the Group C was given intravenously 10 mg dexamethasone solution 1 h before the surgery and repeated 6 h after surgery. To support the double-blind study, patients in group A were treated with 2 doses of a normal saline solution and patients in group B were treated also normal saline solution 6 h after surgery. All drugs were administered by a nurse who was not involved in the study. The patients, investigators, and statisticians were all blind during the study.

Surgical technique
All patients were performed general anesthesia, which was administered by the same anesthetists. All TKAs were performed by 1 senior orthopedic surgeon through a midline skin incision, medial parapatellar approach. All patients have used the PFC Sigma PS (DePuy Orthopedics Inc., Warsaw, IN, USA) prosthesis. All of the wound closed at about 45°of knee bends. The arthroscopy closure was performed using an interrupted figure-of-eight #1 EthibondTM (Ethicon, Somerville, NJ, USA), a subdermal closure using interrupted buried simple 2–0 Monocryl TM (Ethicon) and staples for skin closure. All patients were given intraoperatively 20 mg/kg tranexamic acid (Chongqing Lummy Pharmaceutical Co., Ltd. China) 10 min before the skin incision, and repeated 3 h after surgery. No patients used the tourniquet, drainage tube, femoral nerve block and/or intravenous patient-controlled analgesia.

Postoperative care
All patients received cefturoxime 1.5 g 2 h before the operation to prevent infection. After the operation, the patient was transferred to the anesthesia recovery unit for 2 h and then sent to the inpatient ward. A cold pack was applied to the surgical site 2 days. Daily gait rehabilitation program and weight training were conducted by a physiotherapist on the first day after surgery.

All patients received the same management for pain and PONV. Multimodal oral analgesic drugs (200 mg q12 h celecoxib, 75 mg q8 h pregabalin) were administered for pre-emptive analgesia 1 day before the surgery. After the surgery, the pain levels of all patients were measured using a visual analogue scale (VAS, 0- no pain, 10 - worst imaginable pain). The routine analgesia regimen remains the same as before surgery when the VAS level of the patient was lower than 4. Oral oxycodeone (10 mg q8 h) was used when the VAS level of the patient was between 4 and 6, and intramuscular injection of pethidine hydrochloride (100 mg) was used when a patient reported pain greater than 6. The severity of nausea of all patients was measured using VAS (VAS, 0-on nausea, 10- worst imaginable nausea). Metoclopramide (10 mg) was injected intravenously as the first-line antiemetic rescue treatment when PONV occurred two or more times or the VAS level was greater than 4. An intramuscular injection of ondansetron (5 mg) can be used as the second-line antiemetic rescue option when severe nausea persists after two doses of metoclopramide for a 30-min interval.

All patients were given subcutaneously low molecular-weight heparin (LMWH, 0.2 mL, 2000 IU) at 6 h postoperatively, and repeated with a full dose at 24-h intervals.
(0.4 mL, 4000 IU) until discharge. After discharge, 10 mg rivaroxaban (Xarelto, Bayer, Germany) was administered orally for 15 days to prevent thrombosis [28]. Intermittent pneumatic compression device was routinely applied on the calves of patients until walking. Doppler ultrasound examination was used assessing deep vein thrombosis (DVT) at the time of discharge and at 1, 3-month follow-up assessments, or at any time clinically suspected DVT. Pulmonary embolism (PE) was diagnosed on the basis of clinical symptoms and chest computed tomography (CT) scans.

Outcome measurements
The outcomes were evaluated including the inflammation reaction of CRP and IL-6, pain level (VAS score) and the number of patients requiring analgesic rescue drugs (Oxycodone and Pethidine hydrochloride), the severity of nausea (VAS score), the incidence of PONV and the number of patients requiring antiemetic rescue (Metoclopramide and Ondansetron). CRP, IL-6, pain level, the severity of nausea, and PONV were routinely tested preoperatively and at 24, 48, and 72 h postoperatively. Nausea was defined as a subjective feeling of unpleasant related to awareness of the urge to vomit. Vomiting is the forcible discharge of stomach contents from the mouth. ROM and a six-point satisfaction questionnaire [5] was assessed at the time of discharge. The LOS and wound-related complications were recorded carefully.

Statistical analysis
The sample size of the current study was calculated, as previously described by Lunn [24], using VAS score as the primary outcome; it was determined that, for 90% power and a significance level of 0.05, requiring 24 patients in each group. With the consideration of exclusion, we decided to include 50 patients in each group. One-way ANOVA and Tukey’s post-hoc were used to compare the quantitative data, such as CRP, IL-6, pain level, the severity of nausea, and ROM. The Pearson chi-square test or Fisher exact test was used for comparing qualitative data, such as the incidence of PONV, patient satisfaction, and complications. All analyses were performed using SPSS version 22.0, significance was set at \( P < 0.05 \).

Results
Baseline characteristics
During the recruitment period from January 2017 to October 2017, 165 patients with osteoarthritis requiring unilateral primary TKA were scheduled. Among these patients, 15 of these patients were excluded for the following reasons: 6 patients with glucocorticoid 3 months before surgery, 3 had alcohol dependence, 5 declined to participate, 1 had an infection. Thus, 150 patients were eventually included in the analysis, 50 patients were randomized to each group (Fig. 1).

No patients were lost during the follow-up. Table 1 summarizes the baseline characteristics of the 3 groups. There were no statistically significant differences in age, gender, BMI, American Society of Anesthesiologists, preoperative Hb, Hct, CRP, IL-6, ROM and VAS among the 3 groups of patients.

Inflammation marks
The mean CRP and IL-6 increased postoperatively in all patients after the surgery. The mean level of CRP peaked 48 h postoperatively among the 3 groups. It was significantly lower in Group C and Group B than Group A at 24 (\( P < 0.001, P < 0.001 \)), 48 (\( P < 0.001, P < 0.001 \)), and 72 h (\( P < 0.001, P < 0.001 \)) postoperatively. The mean level of CRP in Group C was lower than Group B at 24 h (\( P < 0.001 \)) postoperatively, however, it was no statistical significance at 48 (\( P = 0.081 \)) and 72 h (\( P = 0.057 \)) postoperatively (Fig. 2).

The mean level of IL-6 peaked in Group C and B at 48 h postoperatively compared with Group A at 24 h postoperatively. It was significantly lower in Group C and Group B than Group A at 24 (\( P < 0.001, P < 0.001 \)), 48 (\( P < 0.001, P < 0.001 \)), and 72 h (\( P < 0.001, P < 0.001 \)) postoperatively. Although, the mean level of IL-6 in Group B was slightly greater than Group C at 24 (\( P = 0.133 \)), 48 (\( P = 0.073 \)), and 72 h (\( P = 0.075 \)) postoperatively, it was no statistical significance (Fig. 3).

Pain level and rescue analgesic
The postoperative mean VAS pain score was significantly lower in Group C than in Group A at 24 h (\( P < 0.001 \)), 48 h (\( P = 0.037 \)) postoperatively and compared with B 24 h (\( P = 0.030 \)) postoperatively. The differences were also statistically significant between Groups B and A at 24 h (\( P = 0.012 \)) postoperatively (Fig. 4).

Similar to the pain level, the number of patients requiring oxycodone and pethidine hydrochloride was lower in Group C compared with Group A at 24 h (\( P < 0.001, P < 0.001 \)) and 48 h (\( P = 0.003, P < 0.001 \)) postoperatively, and it was also lower in Group B than Group A at 24 h postoperatively (\( P = 0.027, P = 0.034 \)). The level of pethidine hydrochloride was less in Group C than B at 24 h postoperatively (\( P = 0.003 \)) (Table 2).

Intensity of nausea, PONV, and rescue antiemetic
The intensity of nausea in Group C was lower than Group A at 24 h (\( P = 0.009 \)) and 48 h (\( P = 0.005 \)) postoperatively and compared with Group B at 24 h (\( P = 0.027 \)) postoperatively, and it was also lower in Group B than Group A at 24 h postoperatively (\( P = 0.041 \)) (Table 3).

Similar to the intensity of nausea, the incidence of PONV was lower in Group C than Group A at 24 (\( P = 0.002 \)), 48 (\( P = 0.041 \)) and 72 h (\( P = 0.031 \)) postoperatively, and there
was also a significant difference between Groups B and A at 24 h ($P = 0.019$) postoperatively (Table 3).

The number of patients requiring metoclopramide was lower in Group C compared with Group A at 24 ($P < 0.001$), 48 ($P = 0.025$) and 72 h ($P = 0.035$) postoperatively, and it was also lower in Group B than Group A at 24 h ($P = 0.017$) postoperatively (Table 3).

No three-group differences in the number of patients requiring ondansetron were found at 24 ($P = 0.064$), 48 ($P = 0.132$) and 72 h ($P = 1$) postoperatively (Table 3).

Table 1 Preoperative demographics

| Variables                  | Group A (n = 50) | Group B (n = 50) | Group C (n = 50) | P Value |
|---------------------------|------------------|------------------|------------------|---------|
| Age (y)                   | 67.40 ± 3.34     | 66.90 ± 4.62     | 66.38 ± 3.38     | 0.414   |
| Gender (M/F)              | 32/18            | 33/17            | 30/20            | 0.818   |
| Weight (kg)               | 65.52 ± 4.99     | 65.22 ± 4.81     | 66.38 ± 3.84     | 0.423   |
| Height (cm)               | 159.38 ± 6.76    | 158.06 ± 5.81    | 157.92 ± 6.86    | 0.465   |
| BMI (kg/m²)               | 25.85 ± 2.08     | 26.14 ± 1.98     | 26.70 ± 2.08     | 0.109   |
| ASA                       | 1.98 ± 0.65      | 1.94 ± 0.65      | 2.02 ± 0.62      | 0.824   |
| Preop.Hb (g/L)            | 13.42 ± 0.55     | 13.45 ± 0.53     | 13.39 ± 0.56     | 0.858   |
| Preop.Hct (L/L)           | 39.84 ± 1.26     | 39.87 ± 1.17     | 39.74 ± 1.25     | 0.867   |
| Preop.CRP (mg/L)          | 3.23 ± 0.96      | 3.29 ± 0.76      | 3.25 ± 0.93      | 0.950   |
| Preop.IL-6 (pg/mL)        | 4.05 ± 1.10      | 4.15 ± 1.15      | 4.11 ± 0.47      | 0.859   |
| Preop. ROM                | 94.54 ± 3.40     | 93.90 ± 3.42     | 93.89 ± 4.15     | 0.594   |
| Preop. VAS                | 5.16 ± 0.68      | 5.32 ± 0.82      | 5.22 ± 0.68      | 0.542   |
| Duration of surgery (min) | 66.84 ± 3.30     | 67.92 ± 3.30     | 68.02 ± 2.83     | 0.120   |

Abbreviations: y years, M male, F female, R right, L left, BMI body mass index, ASA American Society of Anesthesiologists, Preop preoperative, Hb hemoglobin, Hct hematocrit, CRP C-reactive protein, IL-6 interleukin 6, ROM range of motion, VAS visual analogue scale

P value indicates a significant difference among the groups

* was analyzed by the one-way ANOVA;
† was analyzed by the Pearson chi-square test or the Fisher exact test
ROM, LOS, patient satisfaction, and complications
At the time of discharge, the ROM in Group C was better than in Group A ($P < 0.001$) and B ($P = 0.001$), but it was no differed in the other subgroup in another subgroup. The average LOS in Group A, B, C were 5.02 ± 0.62, 4.94 ± 0.84, and 4.82 ± 0.72 days respectively, no differences were found ($P = 0.393$). Patients in Group C had significantly higher satisfaction ratings than Groups A ($P = 0.002$) and B ($P = 0.043$) (Table III), no benefits in Group B relative to Group A was found ($P = 0.298$) (Table 3).

No DVT and PE was found in any of the patients, however, 9 patients (group A, 3 cases, group B, 3 cases, group C, 5 cases) developed intramuscular venous thrombosis. 2 patients from Group C and 1 patients from Group B had superficial infection during the 3-month follow-up period, which was controlled by dressing change and oral antibiotics. No gastrointestinal hemorrhage occurred (Table 3).

Discussion
The most important finding of this study is that patients in Group C who were intravenously administered 10 mg dexamethasone 1 h preoperatively and repeated 10 mg at 6 postoperatively can significantly reduce the postoperative level of CRP and IL-6, decrease the incidence of PONV and receive additional analgesic and antiemetic effects, and achieve a better ROM and patient satisfaction, without increasing the risk of wound-related complications when compared with patients in Group A and B.

TKA is one of the most effective methods to treat knee diseases [1, 2]. However, surgical trauma following TKA often results in severe postoperative inflammation, which is associated with postoperative pain and PONV [8, 9]. As a result, the fast-track treatment of the patients was hampered postoperatively. Glucocorticoids are known for their analgesic, anti-inflammatory, and anti-emetic effects, although the mechanisms are unclear. In using corticosteroids, therefore, its pharmaceutical ingredients enter the surrounding tissue and reduce the inflammatory response at the site of surgical trauma, thus providing effective pain relief. Dexamethasone is a kind of synthetic glucocorticoid with high bioavailability and long acting time. In the current study, significant increases in CRP and IL-6 levels
were found in the three treatment groups, however, CRP and IL-6 levels increased significantly less in Groups C and B compared with Group A at 24, 48, and 72 h. It was also observed to be lower in Group C than in Group B. Thus, our findings suggest that intravenous dexametha-
sone administered 1 h preoperatively and repeated at 6 h postoperatively reduced the postoperative inflammatory response compared to Groups A and B.

Compared with the level of pain preoperatively, pain de-
clined after TKA among the three groups. As previously
reported, the analgesic effect of glucocorticoid is achieved
by inhibiting phospholipase, thus blocking the pathway of
cyclooxygenase and lipooxygenase in the inflammatory
chain reaction [29]. At the same time, it can also inhibit
the level of bradykinin [30] in tissues and the release of
neuropeptides from nerve endings [31], both of which
may enhance the sense of injury in inflammatory tissues
and surgical wounds. An Randomized Controlled Trial
(RCT) performed by Koh et al. [22] prospectively evalu-
ated 269 TKAs randomized to receive dexamethasone (10
mg) combined with ramosetron or ramosetron alone.
These results suggest that patients with dexamethasone
experienced lower pain and consumed fewer opioids dur-
ing the 6 to 24 h postoperative. Similarly, another RCT
study by Xu et al. [32] involving 108 TKA patients divided
into 2 groups of 54 patients. The two treatment groups
were either given two doses of 10 mg IV dexamethasone
or placebo, the study found that the pain at rest and walk-
ing was lower at 24 h postoperatively in the dexametha-
sone group. The results in current study echo those
findings. We showed a statistically significant reduction of
the VAS score of pain in Group C than Group A at 24 and

![Fig. 4 The level of pain in all groups. Pre-OP = preoperative, post = postoperative. A significant difference among the 3 groups as calculated with one-way ANOVA. † Significantly different from the Group B. # Significantly different from the Group C.]

| Variables                              | Group A (n = 50) | Group B (n = 50) | Group C (n = 50) | P Value |
|----------------------------------------|-----------------|-----------------|-----------------|---------|
| Oxycodone-post 24 h (n)‡               | 28§#            | 17 #            | 8               | 0.001   |
| Oxycodone-post 48 h (n)‡               | 19 #            | 11              | 6               | 0.009   |
| Oxycodone-post 72 h (n)‡               | 8               | 5               | 3               | 0.265   |
| Pethidine hydrochloride-post 24 h (n)‡ | 22§#            | 12              | 6               | 0.001   |
| Pethidine hydrochloride-post 48 h (n)‡ | 14 #            | 7               | 2               | 0.004   |
| Pethidine hydrochloride-post 72 h (n)‡ | 3               | 1               | 0               | 0.166   |
| Metoclopramide-post 24 h (n)‡          | 21§#            | 10              | 7               | 0.003   |
| Metoclopramide-post 48 h (n)‡          | 12 #            | 7               | 3               | 0.039   |
| Metoclopramide-post 72 h (n)‡          | 6 #             | 2               | 0               | 0.025   |
| Ondansetron-post 24 h (n)‡             | 7               | 3               | 1               | 0.064   |
| Ondansetron-post 48 h (n)‡             | 2               | 0               | 0               | 0.132   |
| Ondansetron-post 72 h (n)‡             | 0               | 0               | 0               | 1       |

Abbreviations: post postoperative, h hours, n number
‡ was analyzed by the Pearson chi-square test or the Fisher exact test
P value indicates a significant difference among the groups
§Significantly different from the Group B. # Significantly different from the Group C
Furthermore, the requirements of oxycodone and pethidine hydrochloride were significantly lower in Group C. The antiemetic effects of dexamethasone were well documented [17, 19, 22, 32] and supported in our study. However, the mechanism by which glucocorticoids relieve PONV is not fully understood. Its effect may be mediated by the inhibition of prostaglandin synthesis or the inhibition of endogenous opioid release [33]. The current study showed that two doses of dexamethasone were more effective in preventing the PONV and reducing the intensity of nausea than the single dose or without dexamethasone groups. The results are consistent with previous studies [10, 22, 32] suggesting that dexamethasone has a better antiemetic effect. In a recent meta-analysis of 3 randomized controlled trials [34], dexamethasone not only reduces postoperative pain level and opioid consumption within 48 h but also reduces postoperative PONV. Although few previous studies have investigated the antiemetic efficacy of two doses of low-dose dexamethasone after TKA. The current results as well as previous studies [10, 32] suggest that the use of multiple low doses of dexamethasone has a stronger antiemetic effect on the early stage of PONV than a single dose of dexamethasone. The results therefore suggest that the repeated administration of dexamethasone 6 h postoperatively can effectively reduce the incidence of PONV. Additionally, functional outcome assessments in our study demonstrated a better ROM in Group C. The outcomes might explain the significantly higher satisfaction ratings of patients in Group C at the time of discharge.

However, the optimal routes and doses of dexamethasone remain controversial. A range of doses from 4 to 10 mg in primary TKA has been established in most studies [22, 35]. Barnes et al. [36] suggested that glucocorticoids bind to intracellular glucocorticoid receptors, which are mainly mediated by the synthesis of transcriptional proteins. Therefore, the starting time of biological action is generally 1–2 h [29], and it was reasonable to give dexamethasone 1 h before the surgery so that it reached its plasma concentration at the beginning of resuscitation in this study. In addition, since early media-activated metabolic reaction occurs immediately after surgical incision [37], it is also reasonable to give dexamethasone 1 h before the surgery to obtain a potential therapeutic effect postoperatively. As previously reported [22, 27], patients still have to deal with pain and PONV with single-dose dexamethasone. Thus, we added

| Variables                             | Group A (n = 50) | Group B (n = 50) | Group C (n = 50) | P Value |
|---------------------------------------|-----------------|-----------------|-----------------|---------|
| Intensity of Nausea-post 24h⁷         | 2.96 ± 1.24§#   | 2.38 ± 1.07§#   | 1.76 ± 1.24     | 0.001   |
| Intensity of Nausea-post 48h⁷         | 1.66 ± 0.82§#   | 1.38 ± 0.90#    | 1.12 ± 0.82     | 0.008   |
| Intensity of Nausea-post 72h⁷         | 1.18 ± 0.77#    | 0.94 ± 0.73#    | 0.74 ± 0.85     | 0.023   |
| PONV-post 24 h⁸                       | 22§#            | 11              | 8               | 0.004   |
| PONV- post 48 h⁸                      | 14 #            | 8               | 5               | 0.058   |
| PONV- post 72 h⁸                      | 10 #            | 4               | 2               | 0.026   |
| Satisfaction level (n)‡               |                 |                 |                 | 0.007   |
| Very satisfied                        | 18 #            | 23               | 35              |         |
| Somewhat satisfied                    | 14              | 17               | 11              |         |
| Neither satisfied nor dissatisfied    | 11              | 6                | 4               |         |
| Somewhat dissatisfied                 | 7               | 4                | 0               |         |
| Very dissatisfied                     | 0               | 0                | 0               |         |
| ROM*                                  | 99.66 ± 2.60 #  | 100.70 ± 2.37 #  | 102.48 ± 1.99   | 0.001   |
| LOS (days)*                           | 5.02 ± 0.62     | 4.94 ± 0.84      | 4.82 ± 0.72     | 0.393   |
| DVT (n)‡                              | 0               | 0                | 0               | 1       |
| PE (n)†                               | 0               | 0                | 0               | 1       |
| Intramuscular thrombosis (n)³         | 3               | 3                | 5               | 0.675   |
| Superficial infection (n)³            | 0               | 1                | 2               | 0.360   |
| Gastrointestinal hemorrhage (n)³      | 0               | 0                | 0               | 1       |

Abbreviations: Post postoperative, h hours, n number, PONV postoperative nausea and vomiting, ROM range of motion, LOS length of stay, DVT deep vein thrombosis, PE Pulmonary embolism

*was analyzed by the one-way ANOVA;
‡ was analyzed by the Pearson chi-square test or the Fisher exact test
P value indicates a significant difference among the groups
§Significantly different from the Group B.
# Significantly different from the Group C
an additional 10-mg dose of dexamethasone at 6 h postoperatively, assuming that it would have a meaningful clinical benefit.

Although TKA is associated with thrombosis [3, 38], and glucocorticoids are associated with wound healing and postoperative infection, previous studies using low or high doses of glucocorticoids have not shown that glucocorticoids are associated with these complications during the perioperative period [22, 32, 34]. In our study, we also found that the additional low dose of dexamethasone was given at 6 postoperatively, and no patients had an obvious adverse effect and/or complication during postoperative follow-up. It is known that synthetic glucocorticoids, such as dexamethasone, prescribed in daily care can induce hypertension. However, the exact mechanism by which glucocorticoids may induce hypertension is unclear [39]. Some evidence supports the fact that glucocorticoids may actually have nothing to do with elevated blood pressure in the first few weeks. Gabriel et al. [40] reported that 15.3% of 124 patients with rheumatoid polymyalgia prescribed glucocorticoid treatment for hypertension, and 26.3% of 57 patients who received non-steroidal anti-inflammatory drugs had hypertension. Furthermore, Fardet et al. [41] suggested that the increase of blood pressure during the first months of exposure to synthetic glucocorticoids seems clinically nonsignificant. At the same time, there was also no evidence that perioperative dexamethasone administration is associated with increased postoperative glucose levels (> 200 mg/dl) or higher maximum glucose levels in total joint arthroplasty [42]. Therefore, we believe that there is evidence to support that two doses of low-dose preoperative treatment with dexamethasone are safe in TKA procedures.

This study had some limitations. The follow-up period for assessing functional outcome was 24 h, 48 h and 72 h postoperatively; therefore, this study does not show the long-term effects of dexamethasone. Second, although this study showed a lower incidence of wound-related complications, a larger sample size is required to adequately assess the significant differences in adverse events. Third, two doses of low-dose dexamethasone showed better clinical results, but the best method and dose of dexamethasone and whether a further use is needed to produce additional results remain unclear.

Conclusions
The administration of 10 mg dexamethasone 1 h before the surgery, and repeated at 6 h postoperatively can significantly reduce the level of postoperative CRP and IL-6 and the incidence of PONV, relieve pain, achieve an additional analgesic effect, and improve the early ROM compared with the other two groups in TKA.

Abbreviations
BMI: Body mass index; CRP: C-reactive protein; DVT: Deep vein thrombosis; IL-6: Interleukin 6; LOS: Length of stay; PBV: Patient’s blood volume; PE: Pulmonary embolism; PONV: Postoperative nausea and vomiting; ROM: Range of motion; TKA: Total knee arthroplasty; VAS: Visual analogue scale

Acknowledgements
The authors would like to thank Dr. Li Chen (chenli930@scu.edu.cn) from Analytical & Testing Center Sichuan University for her help with image processing and data analysis, and I would also like to thank Dr. Shuting Li (447623681@qq.com) from Department of Ultrasonography, West China Hospital, Sichuan University, for providing diagnosis of venous thrombosis.

Funding
This study was funded by the National Natural Science Foundation of China Program (No. 81601936, No. 81672219), for providing support of design and drafted the manuscript; and it was funded by the Science and Technology Department of Sichuan Province (No. 2017JFZ0056 and No. 2018H10141), for providing support of data acquisition and language modification; and it was also funded by the Health Department of Sichuan Province (N0.18ZD016), for providing support of interpreted the data and revised the manuscript.

Availability of data and materials
All data and materials are contained within the manuscript.

Authors’ contributions
BS, YZ, and YGW conceived, designed and coordinated the experiments and also funded by the Health Department of Sichuan Province (N0.18ZD016), for providing support of design and drafted the manuscript. BS, YGW, YZ, XCB and HZX contributed to data acquisition, YZ, YGW, HZX, XXL and YMM analysed and interpreted the data. XCB, HZX, XXL and YMM revised the manuscript. XXL and YMM corrected language. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of West China Hospital (No. 201302007). All participants will be required to provide written informed consent to participate.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, Sichuan Province, China. 2Department of Pediatrics, West China University Second Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. 3Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.

Received: 26 September 2018 Accepted: 22 November 2018
Published online: 01 December 2018

References
1. Wu Y, Zeng Y, Bao X, Xiong H, Hu Q, Li M, Shen B. Comparison of minimally invasive subvastus approach versus medial parapatellar approach in primary total knee arthroplasty. Int J Surg. 2018;57:15–21.
2. Kurtz S, Ong K, Lau E, Mowafat F, Halpern F. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780–5.
3. Wu Y, Zeng Y, Li C, Zhong J, Hu Q, Pei F, Shen B. The effect of postoperative limb positioning on blood loss and early outcomes after primary total knee arthroplasty: a randomized controlled trial. Int Orthop. Epub 2018 Oct 23.
4. Filos KS, Lehmann KA. Current concepts and practice in postoperative pain management: need for a change? Eur Surg Res. 1999;31:97–107.
5. Huang Z, Xie X, Li L, Huang Q, Ma J, Shen B, Kraus VB, Pei F. Intravenous and topical tranexamic acid are equally effective to tourniquet use for primary total knee arthroplasty: a prospective, randomized controlled trial. J Bone Joint Surg Am. 2017;99(2):203–61.

6. Shen H, Zhang N, Zhang X. J W. C-reactive protein levels after 4 types of arthroplasty. Acta Orthop. 2009;80(3):380–3.

7. Cui Z, Liu X, Teng Y, et al. The efficacy of steroid injection in total knee or hip arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2015;23:2306–14.

8. Kehler H, Jensen TS, Woolf CJ. Persistent post-surgical pain: risk factors and prevention. Lancet. 2006;367:1618–25.

9. Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Arch Intern Med. 1998;158:2124–8.

10. Backes JR, Bentley JC, Politi JR, Chambers BT. Dexamethasone reduces length of hospitalization and improves postoperative pain and nausea after total joint arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2015;24:338–40.

11. Gan TJ, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003;97:62.

12. Aasvang EK, Luna IE, Kehlet H. Challenges in postdischarge function and rehabilitation. Br J Anaesth. 2015;115:861–6.

13. Polkowski GG, Ruh EL, Barrack RN, Nunley RM, Barrack RL. Is pain and dissatisfaction after THA related to early-grade preoperative osteoarthritis? Clin Orthop Relat Res. 2013;471:162–8.

14. Gurunatne R, Pratt DN, Banda J, Fick DP, Khan RJK, Robertson BW. Patient dissatisfaction following Total knee arthroplasty: a systematic review of the literature. J Arthroplasty. 2017;32:3854–60.

15. Dorr LD, Chao L. The emotional state of the patient after total hip and knee arthroplasty. Br J Anaesth. 2004;93:846–10.

16. Zaghiani K, Melmed GY, Berel D, Ovsyanny G, Murrell Z, Fleschner P. A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery. Ann Surg. 2014;259:32–7.

17. Srinivasa S, Kachohekar AA, Yu TC, Hill AG. Preoperative glucocorticoid use in major abdominal surgery: systematic review and meta-analysis of randomized trials. Annu Surg. 2011;254:183–91.

18. Yang XY, Xiao J, Chen YH, Wang ZT, Wang HL, He DH, Zhang J. Dexamethasone alone vs in combination with trancurantaneous electrical acupoint stimulation or tropisetron for prevention of postoperative nausea and vomiting in gynaecological patients undergoing laparoscopic surgery. Br J Anaesth. 2015;115:883–9.

19. Luna IE, Kehlet H, Jensen CM, Christiansen TG, Lind T, Stephensen SL, Aasvang EK. The effect of preoperative intra-articular methylprednisolone on pain after TKA: a randomized double-blinded placebo controlled trial in patients with high-pain knee osteoarthritis and sensitization. J Pain. 2017;18:1476–87.

20. Hartman J, Khaire JS, Habib A, Farokhyar F, Memon M, Adili A. Perioperative systemic glucocorticoids in total hip and knee arthroplasty: a systematic review of outcomes. J Orthop. 2017;14:294–301.

21. Koh JJ, Chang CB, Lee JH, Jeon YT, Kim TK. Preemptive low-dose dexamethasone reduces postoperative emesis and pain after TKA: a randomized controlled study. Clin Orthop Relat Res. 2013;471:3010–20.

22. Jules-Elysee KM, Lipnitsky JY, Patel N, et al. Use of low dose steroids in decreasing cytokine release during bilateral total knee replacement. Reg Anesth Pain Med. 2011;36:36–40.

23. Lunn TH, Kristensen BB, Andersen LO, et al. Effect of high-dose preoperative methylprednisolone on pain and recovery after total knee arthroplasty: a randomized, placebo-controlled trial. Br J Anaesth. 2011;106:230–8.

24. Miyagawa Y, Ejiri M, Kuzuya T, Osada T, Ishiguro N, Yamada K. Methylprednisolone reduces postoperative nausea in total knee and hip arthroplasty. J Clin Pharm Ther. 2010;35:679–84.

25. Home G, Devane P, Davidson A, Adams K, Purdie G. The influence of steroid injections on the incidence of infection following total knee arthroplasty. N Z Med J. 2008;121:U2896.

26. Koh JJ, Chang CB, Jeon YT, Ryu JH, Kim TK. Does ramosetron reduce postoperative emesis and pain after TKA? Clin Orthop Relat Res. 2012;470:1718–27.